Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr:74:103674.
doi: 10.1016/j.breast.2024.103674. Epub 2024 Jan 27.

Breast cancer highlights from 2023: Knowledge to guide practice and future research

Maria-Joao Cardoso  1 , Philip Poortmans  2 , Elżbieta Senkus  3 , Oreste D Gentilini  4 , Nehmat Houssami  5
Affiliations
Review

Breast cancer highlights from 2023: Knowledge to guide practice and future research

Maria-Joao Cardoso et al. Breast. 2024 Apr.

Abstract

This narrative work highlights a selection of published work from 2023 with potential implications for breast cancer practice. We feature publications that have provided new knowledge immediately relevant to patient care or for future research. We also highlight guidelines that have reported evidence-based or consensus recommendations to support practice and evaluation in breast cancer diagnosis and treatment. The scope of selected highlights represents various domains and disciplines in cancer control, from prevention to treatment of early and advanced breast cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest N. Houssami receives funding via a NBCF Chair in Breast Cancer Prevention grant (EC-21-001) and a NHMRC Investigator (Leader) grant (1194410); MJ Cardoso and O Gentilini receive institutional funding as Leading Investigator and Principal Investigator of the Project: 101057389 — CINDERELLA — HORIZON-HLTH-2021-DISEASE-04. Maria-Joao Cardoso honoraria: AstraZeneca, Eli Lilly, MSD, Roche, Novartis. Oreste Gentilini honoraria: MSD, Astra-Zeneca, BD, Bayer, Eli-Lilly. Elżbieta Senkus honoraria: AstraZeneca, Cancérodigest, Curio Science, Egis, Eli Lilly, Exact Sciences, Gilead, high5md, MSD, Novartis, Pfizer, Pierre Fabre, Roche; travel support: AstraZeneca, Egis, Gilead, Novartis, Pfizer, Roche; contracted research: Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Novartis, OBI Pharma, Pfizer, Roche, Samsung; grants: Pfizer (Stowarzyszenie Różowy Motyl); medical writing: Astellas, AstraZeneca, Eli Lilly; royalties: Springer; leadership or fiduciary role: Stowarzyszenie Różowy Motyl; stock: AstraZeneca, Eli Lilly, Pfizer. Philip Poortmans no conflicts no disclose.

References

    1. Curigliano G., Burstein H.J., Gnant M., Loibl S., Cameron D., Regan M.M., et al. Understanding breast cancer complexity to improve patient outcomes: the St Gallen international consensus Conference for the primary therapy of individuals with early breast cancer 2023. Ann Oncol. 2023;34(11):970–986. - PubMed
    1. Kaidar-Person O., Pfob A., Gentilini O.D., Borisch B., Bosch A., Cardoso M.J., et al. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus. EClinicalMedicine. 2023;61 - PMC - PubMed
    1. Tarantino P., Viale G., Press M.F., Hu X., Penault-Llorca F., Bardia A., et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023;34(8):645–659. - PubMed
    1. Loibl S., Azim H.A., Jr., Bachelot T., Berveiller P., Bosch A., Cardonick E., et al. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC) Ann Oncol. 2023;34(10):849–866. - PubMed
    1. Loibl S., Andre F., Bachelot T., Barrios C.H., Bergh J., Burstein H.J., et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger) Ann Oncol. 2023:1475–1495. - PubMed